Most people receive Keytruda infusions for up to 2 years. But in some cases, treatment may last longer if there’s evidence that the drug is still effective and the side effects are minimal. On the ...

Keytruda reduced the risk of recurrence, progression, or death by 30% vs. standard of care in HNSCC patients. Median event-free survival was 59.7 months with Keytruda vs. 29.6 months with standard ...

Merck’s MRK strong foothold in the oncology space is propelled by its biggest revenue driver, Keytruda. The blockbuster PD-L1 inhibitor alone accounted for more than 50% of the company’s ...

An attempt by Merck & Co. to unlock the microsatellite stable (MSS) metastatic colorectal cancer market has ended in failure. The drugmaker found a fixed-dose combination of Keytruda and an anti-LAG-3 ...

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is ...

CytomX Therapeutics is testing CX-801 with Keytruda in a phase 1 trial for metastatic melanoma, focusing on safety and clinical activity. The trial is conducted at UCSF and the University of ...

Keytruda works by inhibiting the activity of the programmed cell death protein 1 (PD-1), which typically limits the activity of your immune system. Cancer cells often produce PD-1 to prevent your ...

BioNTech has added evidence that PD-(L)1xVEGF-A bispecifics can unseat Keytruda. The German biotech reported an 18-month overall survival rate of 69.7% in a phase 1b/2 breast cancer trial, handily ...

The FDA approved Keytruda for NSCLC based on several clinical trials. Keytruda was studied in people whose NSCLC had spread to other parts of the body (metastatic) and who had received no prior ...